Healthcare providers struggle with EHR adoption

Optimizing electronic health records is still an ongoing effort for most healthcare providers, and the challenges might outweigh the benefits when it comes to revenue cycle performance, according to a new analysis and survey from Navigant and the Healthcare Financial Management Association.

More than half––56 percent––of providers said EHR adoption challenges are equal to or outweighed by the benefits specific to revenue cycle performance. Namely, these providers can’t keep up with EHR upgrades or they underuse functions. Only 44 percent said they can quickly adapt to EHR functional releases.

Fewer providers are likely to spend more on revenue cycle IT next year, with 68 percent saying their revenue cycle IT budgets will increase next year, compared to 74 percent last year, according to the results. More smaller hospitals planned to increase their revenue cycle management IT budgets next year compared to larger hospitals––75 percent and 59 percent, respectively.

“The impact of consumer self-pay on providers will only increase with the popularity of high-deductible health plans and negative changes to the economy,” James McHugh, managing director at Navigant, said in the report. “Providers must take advantage of opportunities to more holistically educate patients on out-of-pocket costs, predict their propensity to pay as early as possible, and secure alternative payers or financing when needed.”

Providers seemed to think increased consumer responsibility for healthcare costs would have less of an impact on their organizations in 2018 compared to 2017.

Looking ahead, organizations were most focused on IT, revenue integrity and RCM improvements and capabilities.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.